Imatib 400 mg

Imatib 400 is a medication used to treat various types of cancer, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is an oral medication that works by inhibiting the activity of the Bcr-Abl protein, which is responsible for the growth and proliferation of cancer cells.

Composition:

Imatib 400 contains Imatinib mesylate, a medication that is a tyrosine kinase inhibitor.

Indications:

Imatib 400 is indicated for the treatment of:

1. Chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast crisis
2. Acute lymphoblastic leukemia (ALL) in adults with Philadelphia chromosome-positive (Ph+) disease
3. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children and adolescents

Mechanism of Action:

Imatinib mesylate works by:

1. Inhibiting the activity of the Bcr-Abl protein, which is responsible for the growth and proliferation of cancer cells
2. Inhibiting the activity of other tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR) and c-kit

Dosage and Administration: The recommended dosage of Imatib 400 is:

• 400mg taken orally once daily, with or without food
• The dose should be taken at the same time each day
• The medication should be taken continuously until disease progression or unacceptable toxicity

Side Effects:

Common side effects of Imatib 400 include:

1. Edema (swelling)
2. Fatigue
3. Nausea and vomiting
4. Diarrhea
5. Rash
6. Abdominal pain
7. Muscle cramps
8. Joint pain

Serious side effects can include:

1. Severe allergic reactions
2. Blood disorders (such as neutropenia, thrombocytopenia, and anemia)
3. Liver damage
4. Cardiac arrhythmias
5. Respiratory problems

Contraindications:

Imatib 400 is contraindicated in patients with:

1. Hypersensitivity to Imatinib mesylate
2. Severe liver or kidney disease
3. Pregnancy or breastfeeding

Precautions:

1. Patients with a history of liver or kidney disease should be closely monitored while receiving Imatib 400.
2. Patients with a history of cardiac disease should be closely monitored while receiving Imatib 400.
3. Patients with a history of blood disorders should be closely monitored while receiving Imatib 400.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of nausea or vomiting.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.